U.S. Markets closed

Key Drugs in Merck’s Oncology Portfolio

Margaret Patrick
Key Drugs in Merck’s Oncology Portfolio

Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)Lenvima growth trendsIn the first quarter, Merck’s (MRK) and Eisai’s Lenvima reported solid uptake across multiple markets, driven mainly by demand in